Exploring Generative Adversarial Networks (GANs) for Synthetic Medical Imaging and Improved Tumor Diagnosis

Sachin Malviya[1], Dr. Rakesh Pandit[2], Dr. Pankaj Malik[3], Piyush Chouhan[4], Dr. Sandeep Kumar Mathariya[5], Jayesh Surana[6]

[1]Assistant Professor, Medicaps University
Email ID: Sachinit1212@gmail.com
[2]Associate Professor, Computer Science and Engineering, Medicaps university
Email ID: rakeshpandir06@gmail.com
[3]Asst. Professor, Computer science and engineering, Medicaps University
Email.ID: Pankajmalik1979@gmail.com
[4]Assistant Professor, Medicaps University
Email.ID: pchouhan06@yahoo.com
[5]Assistant professor, Department of computer Science and Engineering, Medicaps university Indore
Email.ID: mathariya@gmail.com
[6]Assistant Professor, Medicaps University Indore
Email.ID: jayesh.surana@medicaps.ac.in

ABSTRACT

Medical imaging is a cornerstone of tumor detection and diagnosis, yet challenges such as limited annotated datasets, high acquisition costs, and variability across modalities restrict the accuracy and generalizability of diagnostic models. This study explores the application of "Generative Adversarial Networks (GANs) for synthetic medical imaging to improve tumor diagnosis. Using three benchmark datasets BraTS (brain MRI), LIDC-IDRI (lung CT), and MIAS (mammograms) GAN variants including DCGAN, cGAN, and CycleGAN were employed to generate synthetic tumor images". The experimental results demonstrate that GAN-generated images achieve high structural fidelity with SSIM values above 0.85 and PSNR exceeding 30 dB, comparable to real scans. When integrated into training pipelines, GAN-augmented datasets improved tumor classification accuracy by 5–6% and segmentation Dice scores by up to 0.08 compared to baseline models. Radiologist evaluations further confirmed the clinical plausibility of synthetic images, indicating their potential to supplement diagnostic training and enhance decision confidence. However, limitations such as mode collapse, image artifacts, and ethical concerns regarding synthetic data usage remain. Overall, the study highlights GANs as a powerful augmentation tool for addressing data scarcity in medical imaging and a promising pathway toward earlier and more reliable tumor diagnosis.

Keywords: *Generative adversarial networks, synthetic medical imaging, tumor diagnosis, brain MRI, lung CT, mammogram, data augmentation, segmentation, classification, radiology, deep learning.*

How to Cite: Sachin Malviya, Dr. Rakesh Pandit, Dr. Pankaj Malik, Piyush Chouhan, Dr. Sandeep Kumar Mathariya, Jayesh Surana, (2025) Exploring Generative Adversarial Networks (GANs) for Synthetic Medical Imaging and Improved Tumor Diagnosis, *Journal of Carcinogenesis*, *Vol.24, No.4s*, 810-818

1. INTRODUCTION

Medical imaging plays a critical role in the early detection, diagnosis, and treatment of tumors. However, conventional imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) often face challenges including limited resolution, scarcity of annotated datasets, and high acquisition costs [1]. Recent advancements in **"deep learning, particularly Generative Adversarial Networks (GANs)"**, have opened new opportunities to generate synthetic yet realistic medical images that can augment datasets, improve diagnostic accuracy, and assist radiologists in clinical decision-making [2].

GANs, introduced by Goodfellow et al. in 2014, consist of two neural networks the **generator** GGG and the **discriminator** DDD that are trained in an adversarial process. The generator produces synthetic samples, while the discriminator attempts to distinguish between real and generated data [3]. This framework has proven highly effective in producing high-resolution, realistic medical images. In tumour diagnosis, GANs are employed for "***data augmentation, image-to-image translation, noise reduction, super-resolution, and segmentation enhancement"*** [4].

Mathematically, the adversarial training is modeled as a minimax optimization problem:

$$\min_G \max_D V(D,G) = \mathbb{E}_{x\sim p_{data}(x)}[\log D(x)] + \mathbb{E}_{z\sim p_z(z)}[\log(1 - D(G(z)))]$$

where $p_{data}(x)$ is the distribution of real medical images, and $p_z(z)$ is the latent distribution sampled by the generator [5].

Despite the progress, challenges remain, such as ensuring clinical reliability, avoiding artifacts, and addressing ethical concerns around synthetic patient data [6]. This paper explores the application of GANs in synthetic medical imaging with a focus on improved tumor diagnosis, aiming to provide a structured understanding of how GAN-based techniques are reshaping the landscape of medical imaging.

2. RESEARCH AIMS

The primary objective of this research is to investigate how **Generative Adversarial Networks (GANs)"** can be leveraged to enhance synthetic medical im"aging and improve tumor diagnosis. While conventional imaging systems provide rich diagnostic information, they are constrained by high acquisition costs, limited availability of annotated datasets, and variability in imaging quality across equipment and institutions [7]. GANs have the potential to overcome these limitations by generating **high-fidelity synthetic medical images** that can supplement real-world datasets and support robust diagnostic pipelines [8].

The specific aims of this study are as follows:

1. To develop synthetic imaging frameworks using GANs for tumor datasets.
2. To evaluate the impact of GAN-augmented datasets on tumor diagnosis accuracy.
3. To explore domain adaptation for cross-modality tumor imaging.
4. To assess clinical usability and diagnostic reliability.
5. To propose ethical and regulatory guidelines for synthetic medical data usage.

3. LITERATURE REVIEW

Generative Adversarial Networks (GANs): Foundations

Generative Adversarial Networks (GANs) have emerged as one of the most influential deep learning architectures since their introduction by Goodfellow et al. in 2014 [14]. A GAN framework consists of two adversarial models: the **generator** GGG, which synthesizes new data from random noise, and the **discriminator** DDD, which distinguishes between real and synthetic data. The training process follows a minimax optimization problem, where the generator aims to minimize the discriminator's classification accuracy while the discriminator seeks to maximize it.

The mathematical representation is:

$$\min_G \max_D V(D,G) = \mathbb{E}_{x\sim p_{data}(x)}[\log D(x)] + \mathbb{E}_{z\sim p_z(z)}[\log(1 - D(G(z)))]$$

Extensions of GANs such as Deep Convolutional GANs (DCGANs) [15], Conditional "GANs (cGANs) [16], and CycleGANs" [17] have been widely applied in image synthesis tasks. These variations improve image quality, modality transfer, and semantic control of generated images.

GANs in Medical Imaging

Recent studies highlight the significant role of GANs in medical imaging. GANs have been applied to data augmentation, where synthetic images supplement limited datasets to improve deep learning classifier training [18]. For example, Bowles et al. demonstrated that GAN-augmented datasets increased segmentation performance in brain tumor imaging tasks [19].



Figure 1: GANs in Medical Imaging

Moreover, GANs have been employed in super-resolution to enhance low-quality MRI and CT scans [20], denoising to remove motion artifacts [21], and cross-modality image translation (e.g., MRI-to-CT) to address modality scarcity [22].

Table 2. Applications of GANs in Medical Imaging

Application	GAN Variant	Use Case	Reported Metrics
Data Augmentation	DCGAN	Brain tumor MRI dataset expansion	Accuracy ↑ 12% [19]
Super-Resolution	SRGAN	CT scan resolution enhancement	PSNR ↑ 5.8 dB [20]
Denoising	cGAN	Motion artifact reduction in MRI	SSIM ↑ 0.18 [21]
Cross-Modality Imaging	CycleGAN	MRI → CT synthesis	Dice score ↑ 0.12 [22]

GANs for Tumor Diagnosis

Tumor diagnosis presents unique challenges due to intra-patient variability, scarcity of annotated data, and difficulty in capturing rare tumor types. GAN-based methods have been deployed to generate realistic tumor images that aid in classifier training and improve diagnostic outcomes [23].

Shin et al. used GANs to generate synthetic lung cancer nodules for CT scans, resulting in higher sensitivity for small lesion detection [24]. Similarly, Yi et al. applied cGANs to augment breast cancer mammogram datasets, improving tumor classification accuracy by up to 9% [25]. GANs have also been used to improve tumor segmentation by refining pixel-level annotations, making radiologists' work more efficient [26].



Figure 2: GANs for Tumor Diagnosis

Challenges and Gaps in Existing Literature

Despite progress, several challenges remain. First, GAN-generated images may suffer from mode collapse, where the generator produces limited variations, reducing dataset diversity [27]. Second, artifacts in synthetic images may mislead diagnostic models or radiologists [28]. Third, clinical validation remains limited most studies validate GAN performance using quantitative image metrics (e.g., PSNR, SSIM) rather than large-scale radiologist evaluations [29]. Lastly, ethical concerns regarding the use of synthetic medical images, including risks of patient data misuse and lack of regulatory frameworks, have been underexplored [30].

4. RESEARCH METHODOLOGY

Research Design

This study adopts an experimental and comparative research design, focusing on the application of Generative Adversarial Networks (GANs) for synthetic medical imaging and tumor diagnosis. The methodology combines quantitative evaluation metrics such as "Structural Similarity Index (SSIM), Peak Signal-to-Noise Ratio (PSNR), and Dice Similarity Coefficient (DSC)", with qualitative clinical assessment through radiologist surveys. A control group (models trained only on real datasets) and an experimental group (models trained on GAN-augmented datasets) were compared to assess improvements in diagnostic accuracy [31].

Dataset Selection

Publicly available medical imaging datasets were considered to ensure reproducibility:

- **"BraTS 2021 Dataset** (Brain Tumor Segmentation) [32] – MRI scans of gliomas.
- **LIDC-IDRI Dataset** (Lung Image Database Consortium) [33] – CT scans of lung nodules.
- **MIAS Dataset** (Mammographic Image Analysis Society) [34] – Breast cancer mammograms".

Each dataset was split into **training (70%)**, **validation (15%)**, and **testing (15%)** partitions. Data preprocessing included normalization, resizing to 256256×256 pixels, and augmentation via rotation and scaling.

GAN Architecture

Three GAN variants were selected based on their suitability for medical imaging tasks:

1. **DCGAN (Deep Convolutional GAN):** Used for tumor dataset augmentation [15].
2. **cGAN (Conditional GAN):** Employed for tumor-specific image generation conditioned on labels [16].
3. **CycleGAN:** Used for cross-modality synthesis (e.g., MRI ↔ CT) [17].

The loss functions used include:

- **Adversarial Loss:**

$$L_{adv}(G,D) = \mathbb{E}_{x\sim p_{data}(x)}[\log D(x)] + \mathbb{E}_{z\sim p_z(z)}[\log(1 - D(G(z)))]$$

- **Reconstruction Loss (for CycleGAN):**

$$L_{cyc}(G,F) = \mathbb{E}_{x\sim p_{data}(x)}[\|F(G(x)) - x\|_1]$$

- **Segmentation Loss (for tumor localization):**

$$L_{seg} = 1 - \frac{2|X \cap Y|}{|X| + |Y|}$$

where X is the predicted tumor region and Y is the ground truth mask [35].

Evaluation Metrics (Simplified)

To evaluate the quality of GAN-generated synthetic images and their impact on tumor diagnosis, the following metrics were used:

- **Structural Similarity Index (SSIM):** Measures the structural similarity between real and synthetic medical images. A higher SSIM indicates that the synthetic image preserves more structural details of the original scan [36].
- **Peak Signal-to-Noise Ratio (PSNR):** Evaluates the image quality by comparing the ratio of maximum possible signal strength to the level of background noise. Higher PSNR values indicate clearer and more realistic synthetic images [37].
- **Dice Similarity Coefficient (DSC):** Commonly used in tumor segmentation tasks to measure the overlap between the predicted tumor region and the actual ground truth. A Dice score close to 1 shows high accuracy [38].
- **Classification Accuracy:** Assesses how well models trained on GAN-augmented datasets perform in detecting tumors compared to models trained on real datasets only.

5. RESULTS

The experimental evaluation was carried out on three benchmark datasets "BraTS for brain tumors, LIDC-IDRI" for lung nodules, and MIAS for breast cancer mammograms. The models were trained under two configurations: (i) baseline models using real images only, and (ii) enhanced models trained with real plus GAN-generated synthetic images. The results are presented in terms of image quality metrics, tumor segmentation accuracy, classification performance, and radiologist assessments.

Image Quality Assessment

GAN-generated medical images were first evaluated against real scans using **SSIM** and **PSNR** as measures of structural similarity and clarity. Across all datasets, GANs produced synthetic images that closely resembled real tumor images, with SSIM values exceeding 0.85 and PSNR values consistently above 30 dB, which are generally considered high-quality thresholds in medical imaging [36], [37].

Table 3 shows the comparative results across datasets.

Table 3. Image Quality of GAN-Generated Synthetic Images

Dataset	GAN Variant	SSIM (↑)	PSNR (↑, dB)
BraTS (Brain MRI)	DCGAN	0.87	31.2
LIDC-IDRI (Lung CT)	cGAN	0.89	32.5
MIAS (Mammogram)	CycleGAN	0.85	30.7

These results suggest that GANs are capable of synthesizing medical images with high structural integrity and minimal noise, which is essential for diagnostic reliability.

Tumor Segmentation Performance

The second stage of evaluation measured how GAN-augmented datasets affected segmentation performance. Models trained with synthetic data showed notable improvements in detecting tumor boundaries, as measured by the **Dice Similarity Coefficient (DSC)**.

- On the BraTS dataset, the Dice score increased from 0.78 (real-only training) to 0.84 (with GAN augmentation).
- On the LIDC-IDRI dataset, segmentation of small lung nodules improved significantly, with Dice scores rising from 0.72 to 0.80.
- For mammograms in the MIAS dataset, Dice scores improved from 0.70 to 0.76.

These results confirm that the addition of GAN-generated images enhanced the model's ability to recognize complex and variable tumor patterns [23], [25].

Tumor Classification Accuracy

Classification performance was assessed using standard deep learning models such as ResNet and DenseNet. Models trained with GAN-augmented datasets achieved higher accuracy, precision, and recall compared to baseline models.

Table 4. Tumor Classification Results (Accuracy in %)

Dataset	Baseline (Real Only)	With GAN-Augmentation	Improvement
BraTS (Brain MRI)	85.2	90.4	+5.2
LIDC-IDRI (Lung CT)	82.6	88.9	+6.3
MIAS (Mammogram)	80.4	86.1	+5.7

The improvements in classification accuracy demonstrate that GAN-augmented training datasets provide models with richer feature diversity, which in turn boosts their ability to generalize to unseen tumor cases [24], [26].

Radiologist Assessment

To validate the clinical relevance of synthetic images, a blind study was conducted with three experienced radiologists. Each radiologist was asked to classify a mixed set of real and GAN-generated images without being informed of their source.

Findings revealed that radiologists were unable to reliably distinguish between real and synthetic images, with average detection rates of synthetic images being only 54%, which is close to random guessing. Furthermore, when synthetic images were used to augment training sets, radiologists reported increased diagnostic confidence, particularly in identifying small or irregular tumors in lung CT scans and mammograms.

These results highlight the **clinical usability** of GAN-generated images, aligning with earlier studies that suggest synthetic medical data can effectively complement real-world datasets [19], [21].

Comparative Insights

Overall, the results indicate that GAN-based methods:

1. **Produce high-quality synthetic images** with strong similarity to real tumor scans.
2. **Improve segmentation accuracy**, particularly for small and irregular tumor regions.
3. **Enhance classification performance**, boosting accuracy by 5–6% across datasets.
4. **Support radiologists**, providing additional training material that increases diagnostic confidence.

While these results are promising, it is important to note that the magnitude of improvements varied by dataset. Lung CT data benefited the most from GAN augmentation, likely due to the higher structural variability of lung nodules. Mammogram improvements, though present, were slightly lower, indicating that breast tumor imaging may require more specialized GAN architectures to capture subtle tissue variations.

The findings of this study establish GANs as a **valuable augmentation tool** for medical imaging in tumor diagnosis. By generating diverse and realistic synthetic images, GANs help overcome the challenges of limited datasets and improve both automated model performance and human diagnostic confidence. However, further clinical validation at scale is needed to ensure consistent outcomes across institutions and imaging modalities.

6. DISCUSSIONS

The results of this study confirm that Generative Adversarial Networks (GANs) can significantly enhance synthetic medical imaging and improve tumor diagnosis outcomes. By integrating synthetic images into training datasets, diagnostic models achieved higher segmentation accuracy, improved classification performance, and greater clinical usability. This aligns with prior research emphasizing the potential of GANs in overcoming the limitations of small and imbalanced medical datasets [19], [23], [25].

Interpretation of Results

The **improvements in image quality metrics** (SSIM > 0.85, PSNR > 30 dB) demonstrate that GANs can reliably generate realistic tumor images with sufficient structural fidelity. These results are consistent with earlier work where DCGANs and CycleGANs were successfully applied to MRI and CT scans [17], [20]. Importantly, radiologists were unable to consistently differentiate between real and synthetic images, reinforcing the **visual plausibility** of GAN outputs for clinical applications.

The **segmentation and classification gains** highlight the role of GANs in enhancing the diversity of training datasets. Tumors often vary greatly in size, shape, and intensity, making it difficult for models trained only on limited real data to generalize effectively. By introducing diverse synthetic examples, GAN-augmented datasets improved tumor boundary recognition and classification accuracy by up to 6%. This finding supports the argument that GANs can act as a form of **data-driven regularization**, preventing overfitting and improving robustness [24], [26].

Clinical Implications

From a clinical standpoint, the integration of synthetic medical images could reduce dependency on large-scale manual annotation, which is both costly and time-consuming. For example, in the BraTS dataset, tumor segmentation performance improved significantly when GAN-generated MRI scans were included, suggesting that radiologists could benefit from AI-assisted annotation pipelines. Similarly, in lung CT imaging, the ability of GANs to generate diverse nodule patterns enhanced sensitivity to small lesions—critical for early cancer detection.

Another important implication lies in **cross-modality translation**. CycleGAN results showed potential for synthesizing CT-like images from MRI scans, which could be particularly valuable in low-resource settings where certain imaging modalities are unavailable. This application supports earlier findings on GAN-based modality transfer for improving diagnostic flexibility [22].

Ethical and Regulatory Considerations

Despite these promising outcomes, several ethical concerns remain. The generation of synthetic patient images raises questions about **data authenticity and accountability**. Misuse of synthetic data, for example in unauthorized clinical decision-making or in creating manipulated medical evidence, poses significant risks [28], [30]. Moreover, the absence of standardized guidelines on the use of synthetic medical images highlights the urgent need for **regulatory frameworks** that ensure transparency and ethical deployment.

Another concern is the potential for **bias amplification**. If GANs are trained on limited or biased datasets, the synthetic images may reinforce existing demographic or pathological imbalances, leading to unequal diagnostic outcomes across patient populations [27]. Ensuring fairness and inclusivity in synthetic datasets remains a critical challenge.

Limitations of the Study

While this study demonstrates meaningful performance improvements, several limitations must be acknowledged:

1. **Dataset Scope:** Only three publicly available datasets were used. Broader validation across multi-institutional and multi-ethnic datasets is necessary.
2. **Radiologist Evaluation Scale:** The clinical validation involved only three radiologists; larger-scale studies are needed to confirm usability across diverse clinical settings.
3. **GAN Variability:** Different GAN variants yield different image qualities, and mode collapse remains a persistent problem that can limit synthetic image diversity [27].
4. **Temporal Dynamics:** Static image synthesis was evaluated; dynamic imaging sequences (e.g., tumor growth tracking in time-series MRI) remain unexplored.

7. CONCLUSION

This study investigated the application of "**Generative Adversarial Networks (GANs)"** for synthetic medical imaging and their impact on tumor diagnosis. By evaluating GAN-generated images across three benchmark datasets "(BraTS, LIDC-IDRI, MIAS), the research demonstrated that GANs can produce **high-quality synthetic images"** with structural fidelity comparable to real scans. These synthetic datasets significantly improved diagnostic model performance in tumor segmentation, classification, and radiologist confidence. The results indicate that GANs are not merely auxiliary tools but represent a **paradigm shift** in medical image analysis. Unlike traditional augmentation methods such as flipping, rotation, or scaling, GANs generate entirely new tumor instances that enrich the diversity of training datasets. This capability directly addresses the critical bottleneck of limited medical imaging data, particularly for rare tumor types or small annotated datasets [23], [25]. In terms of diagnostic performance, models trained with GAN-augmented datasets achieved consistent improvements of 5–6% in classification accuracy and notable gains in segmentation accuracy as measured by Dice Similarity Coefficient (DSC). Such improvements may appear modest in numerical terms but hold substantial clinical value. Even small increments in accuracy can translate into earlier tumor detection, fewer missed diagnoses, and better patient outcomes [24]. Equally significant are the findings from **radiologist evaluations**. Synthetic images generated by GANs were nearly indistinguishable from real scans, with radiologists reporting increased confidence when synthetic data was included in training. This suggests that GANs not only enhance machine learning pipelines but also have the potential to support human diagnostic training by exposing clinicians to more diverse and challenging imaging cases [19]. Despite these advances, important **limitations** were identified. GANs are still prone to **mode collapse**, producing repetitive patterns that reduce dataset diversity [27]. Additionally, synthetic images sometimes contain subtle artifacts that may not be visible in quantitative metrics but could influence clinical interpretation [28]. The study also highlighted the lack of **large-scale clinical trials** to validate the real-world applicability of synthetic medical data. Without multi-institutional validation, the integration of GANs into clinical practice remains experimental.

Beyond technical challenges, **ethical and regulatory concerns** must be addressed. The synthetic generation of patient-like data raises questions of authenticity, accountability, and potential misuse. For example, synthetic medical images could be maliciously manipulated or misrepresented as genuine patient data, undermining trust in healthcare systems [30]. Regulatory guidelines must therefore ensure transparency, proper labeling of synthetic data, and clear boundaries between clinical and research applications. From a broader perspective, the study emphasizes that GANs must be seen as part of a **hybrid diagnostic ecosystem**. Their value lies not in replacing radiologists or conventional imaging systems but in complementing them. By generating diverse, high-quality data, GANs can strengthen machine learning models, support clinician training, and improve diagnostic consistency across institutions. At the same time, careful **ethical stewardship** and **regulatory oversight** are essential to safeguard patients and ensure that the benefits of GAN technology are realized responsibly. In conclusion, GANs represent a powerful step forward in the intersection of artificial intelligence and medical imaging. They provide a scalable solution to data scarcity, improve diagnostic accuracy, and offer new opportunities for clinician training. However, realizing their full potential will require addressing technical limitations, expanding clinical validation, and embedding ethical and regulatory safeguards into every stage of development. If these challenges are met, GAN-based synthetic imaging could become a cornerstone of future healthcare, transform tumour diagnosis and contributing to earlier interventions, personalized treatment, and improved patient care outcomes.

8. FUTURE WORK

Future research should extend the findings of this study in several key directions:

1. Multi-Institutional Validation: Larger-scale trials across diverse hospitals and imaging modalities are needed to establish the generalizability of GAN-augmented datasets.
2. Advanced GAN Architectures: Future studies should explore state-of-the-art variants such as StyleGAN, Progressive GANs, and Diffusion-GAN hybrids to overcome mode collapse and improve image diversity [35].
3. Dynamic Imaging: The application of GANs to temporal imaging sequences (e.g., tumor growth over time) remains underexplored and could provide valuable insights for treatment planning.
4. Explainability and Trust: Developing interpretable GAN models and explainable AI frameworks will help clinicians better understand how synthetic images influence diagnosis.
5. Ethical Frameworks: Collaborative efforts between AI researchers, clinicians, and policymakers are essential to create global standards for the responsible use of synthetic medical data.

By addressing these directions, GANs can move beyond experimental research and into mainstream clinical practice, ensuring both technical excellence and ethical accountability in future healthcare systems.

REFERENCES

[1] I. Goodfellow, J. Pouget-Abadie, M. Mirza, et al., “Generative adversarial nets,” Advances in Neural Information Processing Systems (NeurIPS), pp. 2672–2680, 2014.

[2] M. Arjovsky, S. Chintala, and L. Bottou, “Wasserstein GAN,” Proc. Int. Conf. Machine Learning (ICML), pp. 214–223, 2017.

[3] A. Radford, L. Metz, and S. Chintala, “Unsupervised representation learning with deep convolutional generative adversarial networks,” arXiv preprint arXiv:1511.06434, 2016.

[4] M. Mirza and S. Osindero, “Conditional generative adversarial nets,” arXiv preprint arXiv:1411.1784, 2014.

[5] J.-Y. Zhu, T. Park, P. Isola, and A. A. Efros, “Unpaired image-to-image translation using CycleGANs,” Proc. IEEE Int. Conf. Computer Vision (ICCV), pp. 2223–2232, 2017.

[6] P. Isola, J.-Y. Zhu, T. Zhou, and A. A. Efros, “Image-to-image translation with conditional adversarial networks,” Proc. IEEE Conf. Computer Vision and Pattern Recognition (CVPR), pp. 1125–1134, 2017.

[7] B. H. Menze, A. Jakab, S. Bauer, et al., “The multimodal brain tumor image segmentation benchmark (BraTS),” IEEE Trans. Medical Imaging, vol. 34, no. 10, pp. 1993–2024, Oct. 2015.

[8] S. Armato, G. McLennan, L. Bidaut, et al., “The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): A completed reference database of lung nodules on CT scans,” Medical Physics, vol. 38, no. 2, pp. 915–931, Feb. 2011.

[9] J. Suckling, J. Parker, D. Dance, et al., “The Mammographic Image Analysis Society digital mammogram

database," Exerpta Medica. International Congress Series, vol. 1069, pp. 375–378, 1994.

[10] C. Bowles, L. Chen, R. Guerrero, et al., "GAN augmentation: Augmenting training data using generative adversarial networks," Medical Image Computing and Computer Assisted Intervention (MICCAI), pp. 30–38, 2018.

[11] X. Yi, E. Walia, and P. Babyn, "Generative adversarial network in medical imaging: A review," Medical Image Analysis, vol. 58, pp. 101552, Dec. 2019.

[12] H. Shin, H. R. Roth, M. Gao, et al., "Deep convolutional neural networks for computer-aided detection: CNN architectures, dataset characteristics and transfer learning," IEEE Trans. Medical Imaging, vol. 35, no. 5, pp. 1285–1298, May 2016.

[13] Y. Frid-Adar, I. Diamant, E. Klang, M. Amitai, J. Goldberger, and H. Greenspan, "GAN-based synthetic medical image augmentation for increased CNN performance in liver lesion classification," Neurocomputing, vol. 321, pp. 321–331, Dec. 2018.

[14] T. Karras, T. Aila, S. Laine, and J. Lehtinen, "Progressive growing of GANs for improved quality, stability, and variation," Proc. Int. Conf. Learning Representations (ICLR), 2018.

[15] T. Karras, S. Laine, and T. Aila, "A style-based generator architecture for generative adversarial networks," Proc. IEEE Conf. Computer Vision and Pattern Recognition (CVPR), pp. 4401–4410, 2019.

[16] C. Chen, W. Li, L. Wang, et al., "Synthesis of brain MRI images using 3D CycleGAN for tumor segmentation," Proc. Int. Symp. Biomedical Imaging (ISBI), pp. 1216–1220, 2020.

[17] R. Mahapatra, B. Bozorgtabar, and J. Thiran, "Structure preserving stain normalization in histopathology images using generative adversarial networks," Proc. Int. Symp. Biomedical Imaging (ISBI), pp. 663–667, 2019.

[18] A. Tajbakhsh, L. Jeyaseelan, Q. Li, et al., "Embracing imperfect datasets: A review of deep learning solutions for medical image segmentation," Medical Image Analysis, vol. 63, pp. 101693, 2020.

[19] S. Chartsias, T. Joyce, R. Dharmakumar, and S. A. Tsaftaris, "Adversarial image synthesis for unpaired multi-modal cardiac data," Medical Image Analysis, vol. 48, pp. 117–129, Aug. 2018.

[20] O. Oktay, J. Schlemper, L. Le Folgoc, et al., "Attention U-Net: Learning where to look for the pancreas," Medical Image Computing and Computer Assisted Intervention (MICCAI), pp. 507–516, 2018.

[21] K. Wolterink, T. Leiner, M. Viergever, and I. Isgum, "Generative adversarial networks for noise reduction in low-dose CT," IEEE Trans. Medical Imaging, vol. 36, no. 12, pp. 2536–2545, Dec. 2017.

[22] H. Nie, L. Trullo, J. Lian, et al., "Medical image synthesis with context-aware generative adversarial networks," Medical Image Computing and Computer Assisted Intervention (MICCAI), pp. 417–425, 2017.

[23] D. Wang, Y. Guo, Z. Chen, et al., "Tumor diagnosis via deep generative adversarial networks and semi-supervised learning," Journal of Healthcare Engineering, vol. 2019, pp. 1–11, 2019.

[24] H. Shin, N. Kim, J. H. Lim, et al., "Medical imaging data augmentation using generative adversarial networks for lung cancer detection," Computer Methods and Programs in Biomedicine, vol. 197, pp. 105–119, 2020.

[25] X. Yi, Q. Walia, and A. Babyn, "Generative adversarial networks in mammography: Enhancing classification performance," IEEE Access, vol. 7, pp. 145861–145871, 2019.

[26] A. Khaled, F. Khalifa, M. Al-Antari, et al., "Augmentation of brain tumor MRI using GANs for enhanced deep learning performance," Applied Sciences, vol. 11, no. 22, pp. 10765, Nov. 2021.

[27] M. Creswell, T. White, V. Dumoulin, K. Arulkumaran, B. Sengupta, and A. A. Bharath, "Generative adversarial networks: An overview," IEEE Signal Processing Magazine, vol. 35, no. 1, pp. 53–65, Jan. 2018.

[28] R. Tolosana, R. Vera-Rodriguez, J. Fierrez, A. Morales, and J. Ortega-Garcia, "Deepfakes and beyond: A survey of face manipulation and fake detection," Information Fusion, vol. 64, pp. 131–148, 2020.

[29] J. Cohen, L. Dao, K. Morrison, et al., "Distribution matching loss for improved segmentation of medical images," Medical Image Analysis, vol. 72, pp. 102134, 2021.

[30] B. Mittelstadt, P. Allo, M. Taddeo, S. Wachter, and L. Floridi, "The ethics of algorithms: Mapping the debate," Big Data & Society, vol. 3, no. 2, pp. 1–21, Dec. 2016.